The management of localized prostate cancer is based on stage, grade, PSA, and subjective assessment of comorbidity and life expectancy. Over the last 15 y, stage migration and the improved use of Gleason sum, PSA and TNM staging have led to many treatment options for patients with newly diagnosed localized prostate cancer. At the same time, advances in treatment techniques have helped decrease the long-term complications of surgery and radiotherapy. However, the importance of age and comorbidity, in survival outcomes and treatment decision-making has been largely overlooked. Currently, stage, grade, and PSA are the only quantifiable variables consistently used in research and treatment decision-making. Comorbidity and life expectancy have remained largely subjective variables. Increasing longevity and a rapidly aging population have made age and comorbidity increasingly important factors in clinical research and treatment decision-making. This article reviews the importance of age and comorbidity on treatment decisions and survival outcomes in prostate cancer, as well as their use as objectively quantifiable variables. Examples from the general oncology literature are given. The overview also examines validated comorbidity indices and advocates the use of the Charlson Comorbidity Index (CCI) in research outcomes and treatment decision-making in prostate cancer. Several clinical vignettes are provided to demonstrate the potential clinical utility of the CCI as applied to prostate cancer.
Introduction
Prostate cancer is the most common nondermatological malignancy in men. Of the estimated 220 900 new cases and 28 900 deaths from prostate cancer in 2003, men over the age of 65 y account for 68% of disease and 92% of mortality. 1, 2 With an aging population and improving longevity, this demographic will continue to increase. However, the optimal management of localized prostate cancer is controversial because of questions regarding the benefits of widespread screening and the paucity of randomized clinical trial data demonstrating the therapeutic efficacy of curative therapy over conservative management. Multiple retrospective analyses and consensus panels have concluded that external beam radiotherapy (EBRT) and radical prostatectomy (RP) lead to equivalent outcomes. [3] [4] [5] [6] [7] [8] For selected early stage patients, EBRT, brachytherapy, and RP are also equivalent in survival outcomes, although their complication profiles differ. It is accepted among prostate cancer experts that the choice between various options needs to be made by the patient with his family's and doctor's involvement. That decision should be based on his comfort with the treatment complication profile rather than survival results, as the latter appear equal from various nonrandomized analyses. 9 Stage, grade, and PSA are the most widely accepted prognostic indicators for prostate cancer outcome. Combined with age, subjective weight of comorbid disease, and patient preference, these factors determine which treatment a patient will receive. Generally, curative therapy (RP, EBRT, or brachytherapy) is recommended for patients predicted to have a life expectancy of X10 y. However, the optimal management of patients with shorter life expectancy due to significant comorbidities and advanced age is uncertain as these patients are thought to have competing disease processes that will result in death before that from prostate cancer.
The direct influence of age and comorbid illness on survival outcomes in oncology has long been recognized and recently documented for a variety of malignancies, including bladder, lung, head and neck, colorectal, and breast cancers. [10] [11] [12] [13] [14] [15] [16] [17] In prostate cancer, comorbidity and age have also been shown to affect risk for treatmentrelated side effects and complications, including gastrointestinal (GI) toxicity, genitourinary (GU) toxicity, and post-treatment sexual function. [18] [19] [20] [21] Consequently, many systems for quantifying the impact of comorbidity as a measurable variable have been devised and validated.
This article reviews the current literature on the effect of age and comorbidity on prostate cancer treatment and survival outcomes with the aid of examples from general oncology. It also explores the currently accepted measures for quantification of comorbidity and proposes the use of comorbidity, as measured by the Charlson Comorbidity Index (CCI), as a quantifiable variable on which to base treatment recommendations and outcomes research for prostate cancer. The authors suggest that the use of strict age criteria are inappropriate in the decision to treat elderly prostate cancer patients less aggressively, and that comorbidity is likely to be the more important of the two variables.
Age and prostate cancer Effect of age on treatment in oncology
The elderly population (age X65 y) in the United States is expanding at an unprecedented rate. Current projections suggest an increase in the number of individuals over the age of 65 y from 33.6 million (13%) in 1990 to 70.2 million (20%) by 2030. 22 Longevity is also improving. Current life expectancy for a person reaching 70 y of age is 12.4 y for males and 15.7 y for females. For individuals reaching 80 y, life expectancy is 6.7 y for males and 8.6 y for females. 23 It has been theorized that perceptions about age may inadvertently result in 'under-treatment' of elderly oncology patients. 24 This concern has been documented in several studies of elderly breast cancer patients. For example, in a study of 1174 Canadian women with stage I-II breast carcinomas, Hébert-Crocteau compared treatments received by women aged 50-69 y to those X70 y. After controlling for comorbidity score, women X70 underwent definitive locoregional treatment in only 48.7% of cases, compared with 83.5% of cases in women aged 50-69 y. 25 In their examination of Surveillance, Epidemiology, and End Results (SEER) and Medicare claims data on the use of chemotherapy in older women with breast cancer, Du and Goodwin also found lower rates of chemotherapy administration among the elderly. Receipt of chemotherapy for stage II disease was 30.2, 18.8, 10.8, and 3.7% for women aged 65-59, 70-74, 75-79 , and X80 y, respectively, with similar patterns emerging for all stages of disease. 26 
Effect of age on treatment in prostate cancer
Within the prostate cancer literature, patient age has also been shown to affect biases in treatments offered to patients. For example, in a postal questionnaire provided to 244 British consultants, Donnovan found that urologists chose radical prostatectomy in 64%, curative radiotherapy in 23%, and conservative management in 8% of cases for men of 55 y of age. For a 69 y old, urologists recommended radical prostatectomy in 24%, curative radiotherapy in 41%, and conservative management in 13% of cases. Finally, for the oldest group of patients, aged 75 y, urologists chose curative radiotherapy for 23% and conservative management for 24% of cases, and did not recommend radical prostatectomy in any case. 27 Another retrospective study of 260 000 patients from the national cancer database (NCDB) treated from 1992 to 1994 confirmed that older prostate cancer patients are often treated less aggressively. In that study, 48% of men aged 50-64 y received radical prostatectomy, while 17% received radiotherapy. Among men 75 y of age or older, only 6% received radical prostatectomy while 35% were treated with radiotherapy, indicating a clear bias for surgery in younger patients, and radiotherapy or conservative management in older patients. 28 
Effect of age on prognosis
Widespread controversy exists regarding the importance of patient age in disease behavior in prostate cancer. In several series, onset of disease at a young age has been correlated with more aggressive tumor types and subsequent mortality. [29] [30] [31] [32] Conversely, other studies have shown survival rates among younger patients to be equivalent or even superior to those of elderly patients. 33, 34 A recent meta-analysis of the negative impact of young age on prostate cancer mortality identified 34 studies of 27 551 patients from the Medline Database between 1966 and 2000. After controlling for TNM stage, tumor grade, and PSA, young age failed to prognosticate increased risk of mortality in patients diagnosed since the introduction of PSA screening. 35 Additional evidence suggests that tumor stage and grade may actually advance with age. 36, 37 Carter et al 37 evaluated a surgical series of 492 men undergoing prostatectomy for stage T1c disease, demonstrating a lower probability of 'curable disease' with advancing age, as well as a trend toward higher Gleason score with older age. Furthermore, a recent study of age-related prostate cancer Treatment patterns in prostate cancer WH Hall et al mortality among 381 patients receiving EBRT for localized prostate cancer found lower all-cause and cause-specific survival rates for patients X73 y of age compared with those o73 y of age. 38 As the importance of age in prostate cancer tumor biology remains unclear, it seems illogical to advocate that an elderly patient does not warrant curative therapy based on the misperception that his tumor may be less aggressive.
Comorbidity and prostate cancer Comorbidity and age
As the population ages, it has become increasingly evident that older persons bear the majority of the cancer burden, both in terms of incidence and mortality. 22 The incidence and prevalence of comorbid conditions, such as cardiovascular disease, cerebrovascular disease, hypertension, and diabetes also increases with age. [39] [40] [41] Not surprisingly, a recent analysis of the National Cancer Institute (NCI)/SEER program data by Yancik 22 directly correlated increasing counts of comorbid conditions with advancing age among general oncology patients. A retrospective examination of 34 294 newly diagnosed cancer patients from the Netherlands Eindhoven cancer registry also found a high prevalence of hypertension and cardiovascular disease in its oncology population. Within the Eindhoven registry, increased prevalence of comorbidity was also correlated with advancing age and male gender. Crude prevalence of comorbidity was shown to be highest for patients with tumors of the lung (58%), kidney (54%), stomach (53%), bladder (53%), and prostate (51%). 42 
Cardiovascular disease and prostate cancer
In accordance with studies from the general oncology literature, cardiovascular conditions have been identified as important causes of comorbidity among prostate cancer patients. Newschaffer et al reviewed causes of death in 1207 reported prostate cancer decedents and compared them with 2906 age-matched, nonprostate cancer decedents. A decreased risk of cancer death among older patients (age X85 y) in the prostate cancer cohort was associated with a higher CCI score (OR ¼ 0.61, 95% CI ¼ 0.45-03.82). Similarly, a decreased risk of prostate cancer death was associated with an increased risk of cardiovascular disease (OR ¼ 0.56, 95% CI ¼ 0.36-0.87). As expected, risk of prostate cancer death correlated positively with advanced tumor stage, but negatively with cardiovascular disease, increasing age, and increasing CCI score. 43 In a similar study, the medical records of 584 patients diagnosed with prostate cancer between 1980 and 1984 were analyzed for cause of death. Satariano et al documented 54% of this cohort as having died from prostate cancer, while 46% died from other causes, including cardiovascular conditions, other neoplasms, and respiratory conditions. The authors concluded that, in the nonprostate cancer death group, patients were at a significantly higher risk of cardiovascular death than prostate cancer death (OR ¼ 0.60, 95% CI ¼ 0.39-0.91). 44 
Effect of comorbidity on treatment decision and prognosis
The impact of comorbid illness on treatment recommendations and survival is well documented in the prostate cancer literature. In general, patients undergoing aggressive treatment with RP tend to be younger and healthier than cohorts treated with curative EBRT or brachytherapy. An assessment of 1337 patients with T1-T3M0 prostate cancer patients less than 75 y old found comorbidity to be the most important prognostic factor for 3 y survival. Furthermore, subgroup analysis revealed that individuals treated with RP were younger and had fewer comorbid conditions than patients receiving nonsurgical treatment. 45 Fowler et al examined the impact of pre-existing comorbidities on the survival of 276 men with T1b and T2NXM0 prostate cancer treated with EBRT or RP between 1980 and 1991. A direct relationship between actuarial survival and CCI score (P ¼ 0.00001), as well as a bias toward increasing age and severity of comorbidities was identified within the EBRT group. 46 Additional research has further clarified the prognostic importance of comorbidity scales in prostate cancer and will be discussed elsewhere with respect to the utility of CCI in prostate cancer. 47, 48 Effect of comorbidity on treatment-related side effects
With respect to treatment-related side effects and complications, several studies have documented the significant influence of patient age and comorbidity. Perhaps the most common of these effects is posttreatment impotence. In the surgical literature, age, presurgical potency, and surgical technique have been documented as significant risk factors for post-treatment impotence. 49, 50 However, evaluation of additional patient-related risk factors, such as concurrent illness, is lacking from the surgical literature. Potency probability was studied in 114 patients with T1-T4N0M0 disease undergoing EBRT to a total dose of 65-70 Gy, revealing diabetes (w 2 P ¼ 0.007) and peripheral vascular disease (w 2 P ¼ 0.039) as significant risk factors for post-EBRT impotence. 21 In a study on predictors of urinary retention following brachytherapy, Bucci et al examined 282 patients with T1c-T2b tumors who were receiving neoadjuvant hormonal therapy in combination with I-125 seed implantation. Urinary retention requiring catheterization was observed in 43 (15%) patients, with multivariate analysis revealing high CT to planning ultrasound target volume (CT:PUTV, a measure of prostate edema) (Po0.003), international prostate symptom score (Po0.01), and presence of diabetes (Po0.04) as independent risk factors. Although the authors speculate that lack of steroid administration in diabetic patients may have resulted in the identification of diabetes as a risk factor, no significant relationship was observed between increased CT:PUTV and the presence of diabetes. Additionally, a subgroup analysis revealed an even higher risk of catheterization for patients with both diabetes and vascular disease. 18 Comorbidity has also been associated with generalized pelvic complications. Liu et al explored the risk of acute Tables 1 and 2) .
No studies definitively establish the superiority of one comorbidity scale over another. All four instruments appear in multiple studies; however, head-to-head comparisons of validity are lacking. In one study of 404 women with newly diagnosed breast cancer, for example, CCI, KFI, and the Satariano index were compared, revealing excellent inter-rater reliability between the three scales, but better mortality prognostication with Treatment patterns in prostate cancer WH Hall et al CCI. 55 The Kaplan-Feinstein Index, CCI, and ICED were compared in an evaluation of procedural mortality in a study of 302 patients undergoing transurethral resection of the prostate or prostatectomy for benign prostatic hypertrophy (BPH), demonstrating similar predictive power for 5 y mortality between the three scales. 58 
Discussion
The importance of age and comorbidity in treatment decisions and survival outcomes has long been recognized in oncology. However, tumor stage and grade remain the only quantifiable variables on which treatment decisions and outcome research are based. Age and comorbid illness remain primarily qualitative factors in oncology, despite a growing body of literature that suggests that their use as directly quantifiable variables may add considerably to their prognostic utility. Data on age, comorbid illness, and their combined effect on outcomes exist for a wide variety of cancers, but research into this topic remains relatively immature with respect to prostate cancer.
The concept of integrating comorbidity into a treatment decision-making is not novel. In the pre-PSA era, Clemens et al, for example, proposed a clinical-anatomic staging scale for prostate cancer. Their work showed that integration of host factors, such as age and comorbidity, into an anatomically based staging system offered better distinction between prognostic groups. 59 In a more recent study, Piccirillo compared a composite TNM/ comorbidity staging system to the existing TNM system for squamous cell laryngeal cancer. His findings revealed that the composite system outperformed the conventional TNM system on all major quantitative measures of comparison, including monotonicity of survival gradient, the range of survival gradient, proportionate reduction in predictive errors, proportionate reduction in variance, w 2 for linear trend, and c-statistic. 60 
Application of the CCI
The Charlson Index has been evaluated in several prostate cancer studies as a prognostic indicator for allcause and cause-specific mortality. Sweat et al studied 751 men with prostate cancer undergoing radical prostatectomy and used competing risk analysis to predict mortality. While Gleason score emerged as the only significant predictor of cause-specific mortality, Gleason score and CCI score both predicted all-cause mortality. 48 Gleason score, Charlson Index, KaplanFeinstein Index, and Index of Coexistent Disease were also compared in a retrospective analysis of 451 men aged 65-75 y receiving hormonal vs no treatment within 3 months of diagnosis. Gleason score was again found to be the best independent prognostic factor, but each of the three comorbidity indices demonstrated similar power to predict survival. Additionally, models combining any one of the three comorbidity indices with Gleason score improved predictive power for survival over Gleason score alone. 47 Similar conclusions have been reached by other groups in their use of CCI in prostate cancer models (Table 3) .
Age, prognosis and treatment decisions
As the elderly population grows, an understanding of how to use age in combination with comorbidity becomes increasingly crucial. Age is a pivotal factor in treatment decision-making, and in prostate cancer it greatly affects the treatments clinicians recommend to patients. The current management of prostate cancer does not reflect recent data with respect to elderly patients and the benefits they might gain from increased therapeutic intervention. It is becoming increasingly evident that prostate cancer tumor biology is similar in both young and elderly populations, with some studies pointing toward more aggressive tumor biology in older patients. If prostate cancer outcomes are, in fact, less dependent on age than originally believed, then the question of whether, or to what extent, age should impact treatment choice arises.
A recent Department of Defense analysis of 1018 patients receiving definitive treatment for stage T1-T3 prostate cancer with EBRT, for example, demonstrated that age had no effect on bNED (no biochemical evidence of prostate cancer) when analyzed by decade of life, age o60 vs X60 y, and as a continuous variable. 63 Recent work from the surgical oncology literature on non-small cell lung cancer also suggests that patients should not be denied surgery based on age alone, and that older patients may have similar cancer-specific survival rates compared with their younger cohorts. [64] [65] [66] A study by Brim et al of patients undergoing resection for primary non-small cell lung cancer found that CCI score, rather than age, was a significant predictor for major complications including postoperative mortality. 67 Similar studies from the surgical literature on outcomes from colorectal Treatment patterns in prostate cancer WH Hall et al carcinoma suggest that comorbidity, more than age, impacts mortality. 15 While calendar age should obviously have weight in treatment decisions, it is unacceptable to deny patients appropriate therapy based on strict age criteria. It may, therefore, be completely appropriate to offer a 75-y-old healthy male a radical prostatectomy or curative radiotherapy given a median life expectancy of almost 10 y.
Clinical vignettes
It is unrealistic, at present, to devise a simple equation in which to input all prognostic features for prostate cancer and output a recommendation for the appropriate therapy. However, the more variables for which a numeric value can be calculated, the more objective the decision-making process becomes. The application of CCI along with current life tables to the following examples will provide some insight into the practical application of CCI. Each case will answer two questions: (1) Should curative or noncurative therapy be recommended? (2) Which therapy should be offered based on side-effect profiles, CCI, and patient preferences?
Vignette #1: A 75-y-old former banking executive with a medical history of type II diabetes with peripheral neuropathy, mild CHF (NYHA class I), and peripheral vascular disease presents for treatment of his prostate cancer. He has no family history of prostate cancer. The patient's Gleason score is 3 þ 3 with a PSA of 8, and no palpable disease on digital rectal exam (stage T1c). Based on Partin nomograms, his probability of organ-confined disease is 75%. [68] [69] [70] Application of the CCI reveals a score of 6. Review of current life tables reveals lower quartile, 50th percentile, and upper quartile life expectancy of 4.9, 9.3, and 14.2 y, respectively. Question 1: Should curative or noncurative therapy be recommended? Based on this patient's comorbidities, one might predict that his life expectancy lies somewhere between 4.3 and 9.3 y (between 50th percentile and lower quartile). Consideration of his CCI suggests that he is at moderate to high risk of death from comorbid illness, as well as for treatment-related complications. However, based on life tables alone, his potential life expectancy approaches 10 y. An additional consideration lies in the patient's perioperative risk. Given his high CCI score and the potential for perioperative complication, selection of non-invasive curative therapy, such as EBRT, or expectant management is probably most appropriate.
Question 2: What therapy should be offered based on side-effect profiles, CCI, and patient preferences? Given that the patient and physician are now working from a nonsurgical position, choosing a treatment option should be based on side effects and patient preferences. His remaining options are EBRT, brachytherapy, hormonal therapy, and expectant management, with either radiotherapy or hormonal therapy if progression is detected. After discussing his risk of developing various complications based on his comorbid illnesses, the patient chooses curative management with EBRT.
Vignette #2: An 80-y-old retired physician with a past medical history of essential hypertension and asthma presents with prostate cancer with Gleason sum, stage, and PSA identical to the patient in vignette #2. The patient's family history is significant for a brother who had prostate cancer in his 60s and received treatment with radical prostatectomy. Based on current life tables, his lower quartile, 50th percentile, and upper quartile life expectancy are 3.3, 6.7, and 10.2 y, respectively. The Partin nomograms suggest a 75% likelihood of organconfined disease. [68] [69] [70] The patient's CCI score calculates to 1, and his predicted life expectancy can be estimated to be somewhere between 6.7 and 10.2 y (between 50th percentile and upper quartile). Additionally, the patient states that he would like to have surgery, as his brother obtained cure with the procedure.
Question 1: Should curative or noncurative therapy be recommended? Given a life expectancy of between 6.7 and 10.2 y and low CCI score, it is appropriate to offer the patient curative therapy.
Question 2: What therapy should be recommended based on side-effect profiles, CCI, and patient preferences? The patient can be informed that all of the major complications of treatment have been shown to increase Treatment patterns in prostate cancer WH Hall et al with age. Additionally, he can be informed that EBRT places him higher risk for GI toxicity than the other options, while RP places him at a higher risk for GU toxicity (ie, incontinence). Since he has a very low CCI score, his current comorbidities do not place him at higher risk for treatment-related complications based on the current literature. Ultimately, the patient decides to pursue curative therapy and chooses radical prostatectomy.
Additional considerations
While comorbidity indices have been shown to be invaluable in quantifying concurrent illness, they too are relatively immature in development. In the analysis of the indices detailed previously, Extermann identifies several shortcomings with the current comorbidity scales. These include lack of understanding of whether a few specific diseases or the overall disease burden is more important for prognosis, the lack of ability to distinguish the cumulative vs synergistic effects of multiple conditions, and a lack of understanding or the effect of one condition vs another on mortality and quality of life. 53 Additional directions for future studies should seek to maximize the effectiveness of comorbidity indices by adhering to standardized scales. In one application of CCI to prostate cancer, for example, a cohort with a CCI score of 1 receiving radiation therapy had a significantly greater age-adjusted risk of dying from a comorbid condition than their counterparts receiving prostatectomy. This may have been due to the fact that apparent differences in the severity of comorbidities resulted in exclusion of some patients from surgery. For example, no patients receiving surgery had CHF or dementia, even though these conditions were assigned a weight of 1 on the CCI. 6 If a comorbidity scale is to be useful as a research aid and in treatment decision-making, it must either account for such variation or its users must adhere to its parameters as tightly as possible.
Another concept important to the application of comorbidity indices in oncology lies in the distinction between cause-specific survival and all-cause survival. In this review, comorbidity score was found to have a variable impact on cause-specific survival, while consistently correlating with all-cause survival for prostate and a variety of other cancers. Additionally, the specific reporting of cancer-specific vs all-cause survival was highly variable (Table 3 ). The potential interaction between comorbid disease and the primary cancer complicates the delineation between these two distinct survival outcomes. When a patient is reported to have died from a cause other than cancer, it is important to acknowledge that the cancer, whether or not it directly caused death, was part of that patient's physiology. This effect has begun to receive attention and was recently examined by Newschaffer using the Rothman's synergy index to compare 3549 breast cancer patients to 2114 agematched controls. Although his findings suggested an interaction between breast cancer and comorbid illness, none of his theoretical models achieved statistical significance.
14 While the delineation between cancerspecific survival and all-cause survival may be artificial, and the interaction between comorbid illness and primary cancer awaits demonstration, the use of comorbidity indices in future research should help clarify these issues.
A final reflection lies in the practical application of CCI to clinical practice as well as its integration into outcomes research. While CCI has consistently shown itself to be the fastest and most concise of the validated comorbidity measurement tools, if the data cannot be collected efficiently it is unlikely that CCI will see widespread use in busy clinical practices. Computerized medical record systems promise to make collection of CCI-related data more efficient for both clinicians and researchers. Additionally, simple computer-based queries for concurrent illness data, and eventually CCI score, should become possible.
Conclusion
Recent migrations to more favorable stages [71] [72] [73] and the use of Gleason sum and PSA with TNM staging as prognostic factors has led to many acceptable treatment options based on the individual patient's disease profile. Additional advances, such as nerve sparing and laparoscopic prostatectomy, improved bladder-uretheral anastamotic techniques, 3-D conformal radiotherapy, intensity-modulated radiotherapy, brachytherapy guided by transrectal ultrasound, and the use of neoadjuvant/adjuvant hormonal therapy, have also helped decrease the long-term complications of surgery and radiotherapy. However, age and comorbid illness have received little attention in terms of their importance on treatment decisions and determination of research outcomes. Individuals with advanced age are frequently offered less radical treatment because of misperceptions about their life expectancy. Similarly, individuals with comorbid illness may not be treated appropriately based on perceptions about their life expectancy, ability to tolerate therapy, and potential treatment side effects. If these shortcomings are to be corrected, age and comorbid illness must be integrated into treatment decisions and outcomes research in rational and quantifiable ways. The CCI offers a simple and objective way with which to evaluate concurrent disease as a mathematical variable for use in the treatment recommendations and in comparison of research outcomes.
